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Abstract
STATINS INDUCE APOPTOSIS AND AUTOPHAGY IN PRIMARY
AND TRANSFORMED MAST CELLS
By Patrick A. Paez
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Biology at Virginia Commonwealth University.
Virginia Commonwealth University, 2016
Major Advisor:
John J. Ryan, Ph.D., Professor of Biology, Associate Vice President for Research Development
Statin drugs are widely employed in the clinic to reduce serum low density lipoproteins (LDLs) in
patients with hypocholesteremia. In addition to their cholesterol-lowering effects through HMG
CoA reductase antagonism, isoprenyl lipids necessary for membrane anchorage and signaling of
small G-proteins are abrogated. We previously found that statins suppress mast cell activation in
murine and human cells, suggesting these drugs might be useful in treating allergic disease. While
mast cell function is critical to allergic inflammation, mast cell hyperplasia and survival also
impact these diseases, and were not studied in our previous work. In this study, we describe
Fluvastatin-mediated apoptosis in both primary and transformed mast cells. An IC50 was achieved
between 1-5μM in both systems, and apoptosis was preceded by mitochondrial dysfunction and
caspase release. In addition to apoptosis, our work also uncovered evidence of autophagy, which
can serve as a compensatory mechanism during apoptosis. Interestingly, autophagy appeared to be
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cyto-protective in the primary cells yet cytotoxic in transformed mast cells. These findings offer
insight into the mechanisms of mast cell survival and support the possible utility of statins in mast
cell-associated allergic and neoplastic diseases.
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Keywords
SCF: Stem cell factor
cKIT: (CD117) receptor for SCF
IL-3: interleukin 3
BMMC: Bone marrow derived mast cells
P815: Mastocytoma cell line
KO: Knock out
IgE: Immunoglobulin E
LDL: Low density lipoprotein
IC50: Inhibitory concentration 50%
PI: Propidium Iodide
TBS: Tris-buffered saline
TBS-T: Tris buffered saline with tween 20
DMSO: Dimethyl sulfoxide
BAF A1: Bafilomycin A1
CQ: Chloroquine
MAPK pathway: Mitogen activated protein kinase pathway
ERK: Mitogen activated protein kinase (MAPK)
AKT/PKB: Protein kinase B, a serine/threonine kinase

7

Introduction
Statin drugs were released for consumption by the FDA in the early 1990’s to combat the rising
trend in hypercholesterolemia in the United States. These drugs reduce serum cholesterol and
low density lipoproteins (LDLs), which have been linked to increased risk of coronary heart
disease (CHD) and stroke (1). However, statins have also been noted to have anti-inflammatory
and anti-neoplastic effects that warrant further study. The pharmacological mechanism of statins
is HMG-CoA reductase (HMGCR) antagonism. HMGCR is the rate-limiting step in cholesterol
synthesis, yielding mevalonic acid. While mevalonic acid is processed to cholesterol, side
reactions in this cascade also generate the isoprenoids geranylgeranyl pyrophosphate and
farnesyl pyrophosphate. Isoprenylation is required for Ras, Rac and Rho subcellular localization.
Since these proteins are critical to cellular proliferation, migration, and cytokine production,
there is great interest in determining if isoprenoid blockade is the means by which statins disrupt
cell signaling (2, 3). Understanding this process could lead to new drug targets for inflammatory
and neoplastic disorders.
Epidemiological studies have noted that asthmatic patients prescribed statins experienced
fewer emergency department visits for their allergic conditions as compared to their counterparts
(4, 5). These studies have posed the question of what roles statins play in the cellular and
molecular signaling of sentinel immune cells that provoke the allergic response. Mast cells play
an early role in allergies when activated through the high affinity immunoglobulin E (IgE)
receptor (FcεRI). Antigen-mediated crosslinking of IgE bound to FcεR induces the release of
preformed granules containing proteases and histamine as well as cytokine secretion.
Collectively these mediators induce vasodilation and bronchoconstriction, leading to edema,
dyspenia, tissue damage, and even systemic shock. Exploring the importance of isoprenoid
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inhibition through statin treatment could reveal fundamental aspects of mast cell biology and
offer new therapeutic avenues for allergic disease.
In addition to their role in allergic disease, mast cells can form neoplasms. Mast cell
leukemia is a form of acute myelogenous leukemia (AML) that constitutes approximately 3% of
leukemias. Diagnosis requires one major or three minor criteria. The major criteria for diagnosis
is dense multifocal infiltration of mast cells in the bone marrow or extracutaneous organs. The
four prototypical minor criteria are: >25% of mast cell infiltration in biopsies with atypical
morphology, mast cells in the bone marrow being >25% immature or atypical, D816V CD117
(cKIT) mutation, expression of CD2 and/or CD25, and total serum tryptase exceeding 20ng/mL
consistently (6).
Statins have been shown to induce macroautophagy, hereafter referred to as autophagy
(2). Autophagy has several survival adaptation roles, as it degrades internal organelles to create
energy while in a catabolic state. However, its adaptation properties are dependent on cellular
state and metabolism (7, 8). The autophagic process is often a pro-survival pathway used by
cancer cells in response to nutrient deprivation or various toxic insults such as chemotherapeutic
agents. But autophagy can also be cytotoxic, as it can enhance intracellular apoptotic signals (9).
Interestingly, a recent study has shown that mast cells have a constant autophagic flux necessary
for granule maintenance (10). Statins have been shown to alter autophagy and cause
mitochondrial dysfunction (11). How this may impact mast cell function and survival is
unknown. Statins can also play roles in neoplastic conditions potentially serving both pro- and
anti-metastatic functions. The differences observed were dependent on the cancer type, stage,
and degree of immunological involvement. In one study, Fluvastatin inhibited metastasis of
pancreatic cancer and in another study it was shown to induce apoptosis of transplanted rat
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hepatocarcinoma (12, 13). These studies have provided the interest for studying statin induced
apoptosis and autophagy.
A recent paper from our group demonstrated that statins are powerful suppressors of IgEmediated mast cell activation (14, 15) . Of the statins tested, Fluvastatin was most effective in
suppressing cytokine production. During these studies, we noted that prolonged treatment caused
apoptosis. The current work builds on this initial observation, showing that Fluvastatin induces
both apoptosis and autophagy capable of killing primary or transformed mast cells. We provide
some mechanistic insights, narrowing the focus of Fluvastatin action and offering support for the
possible clinical use of statins in mast cell-associated diseases.

Methods and Materials
Animals:
C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were
maintained at Virginia Commonwealth University (VCU) facilities in accordance with
Institutional Animal Care and Use Committee guidelines (IACUC).

Bone Marrow-Derived Mast cell Cultures (BMMC):
Bone marrow-derived mast cell cultures (BMMC) were extracted from femurs and tibias and
placed in complete RPMI (cRPMI) 1640 medium (Invitrogen Life Technologies, Carlsbad, CA)
containing 10% FBS, 2mM L-glutamate, 10 U/mL penicillin, 10 μg/mL of streptomycin, 1mM
sodium pyruvate, and 10mM HEPES (Biofluids, Rockville, MD), supplemented with SCFcontaining supernatant from BHK-MKL cells and IL-3 from WEHI-3B cells for 21 days. Final
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concentrations of SCF and IL-3 are adjusted to 15 ng/mL and 10 ng/mL, respectively, as
measured by ELISA.

Flow Cytometric analysis:
Apoptosis Analysis:
Propidium Iodide-DNA (PI-DNA) staining was performed on cells after 4 hours to 7 days of
fixation in PI fixation buffer (36% ethanol, 12.8% fetal calf serum, and 50.8% 1X PBS) .
(Thermo Fisher, Waltham, MA). All flow cytometric analysis was done using a BD
FACSCaliber (BD Biosciences, San Jose, CA).
Mitochondrial Staining:
Di(OC6)3 (3,3’-Dihexyloxacarboncyanine iodide), a membrane-permeable dye was used to
analyze mitochondrial integrity at a concentration of 1nM (Enzo Life Sciences, Farmingdale,
NY). Caspase 7/9 activity DEVD assays were used to assess the presence of active caspases
(Thermo Fisher, Waltham, MA). All flow cytometric analysis was done using a BD
FACSCaliber (BD Biosciences, San Jose, CA).
Cell Receptor Staining:
Cell surface staining was conducted using antibodies against the following mouse proteins:
CD117 (c-KIT), CD25, CD2, CD16/CD32, (eBiosciences, Waltham, MA). All flow cytometric
analysis was done using a BD FACSCaliber (BD Biosciences, San Jose, CA).
Autophagy Assessment with Acridine Orange:
Acridine Orange (AO) staining was used for assessment of acidic vesicles associated with the
process of autophagy (Sigma-Aldrich, Saint Louis, MO). Cells were treated with a final
concentration of 1µg/mL for 15 minutes. All flow cytometric analysis was done using a BD
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FACSCaliber (BD Biosciences, San Jose, CA).

Fluorescent Microscopy:
Cells were stained with anti CD16/CD32, FITC cKIT (CD117), and acridine orange at a
concentration of 1µg/mL for 30 minutes. Cells were then washed and spun onto glass slides for
imaging using a Cytospin centrifuge (Thermo Fisher, Waltham, MA) and images were captured
using a Nikon Eclipse E600/ C1 confocal microscope. Images were created using the EZ-C1 3.80
software.

Western Blotting:
Western blots were conducted using standard SDS-PAGE protocol on a 4-20% gradient
polyacrylamide gel. Nitrocellulose membrane (0.45μM) was purchased from Bio-Rad (Hercules,
CA). The following primary antibodies were used: LC3I/II (1:1000), p62 (1:1000), GAPDH
(1:1000), ERK1/2 (1:1000), phospho-ERK1/2 (1:1000), AKT (1:1000), phospho-AKTser473
(1:1000), p85 (1:1000), phospho-p85 (1:1000) (Cell Signaling, Danvers, MO). Western blot
membranes were blocked with TBS-bovine serum albumin (BSA) and primary antibodies
incubated for three days in TBS/0.1% Tween (TBS-T 0.1%) and (0.5% BSA Blocker ™) all
purchased from Thermo Fisher, Waltham, MA). Western blots were read using infraredconjugated secondary antibodies on an Odyssey Imaging System (LI-COR, Lincoln, NE).

Statistics:
Data shown in each figure are the mean ± standard deviations (SD). The number of populations
per experiment is depicted as (N). Graphical and statistical analysis were conducted on Graph
Pad-Prism 7. For comparisons of two samples, a Student’s t-Test was applied unless otherwise
stated. Significance was assigned as follows: *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001.
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Results:
Fluvastatin induces apoptosis in C57BL/6 BMMCs.
We recently published that Fluvastatin suppresses IgE-mediated activation of mast cells and
basophils. Upon further investigation, it was noted that Fluvastatin also causes apoptosis of bone
marrow derived mast cells (BMMC). BMMCs were co-cultured for 72-hours in cRPMI
supplemented with SCF and IL-3 at 10 ng/mL, plus either vehicle (DMSO) or Fluvastatin 10
µM. PI-DNA staining was conducted to detect sub-diploid DNA, indicative of apoptosis. It was
found that over 50% of the BMMCs were undergoing apoptosis by 48-hours and over 90% by
72-hours in Fluvastatin treatment (Figure 1A). A dose response of Fluvastatin was conducted at
72-hours, and an IC50 was found between 1-5µM as determined by PI-exclusion via flow
cytometry (Figure 1B). A 72-hour dose response to Fluvastatin confirmed the presence of active
caspase 3/7, as determined by flow cytometry (Figure 1C). Interestingly, BMMCs treated with
Fluvastatin undergo apoptosis with no discernable cell cycle arrest, even in the 24 hours
preceding detectable (Figure 1D). Instead, all phases of the cell cycle were reduced by
Fluvastatin, with only the apoptotic fraction increasing. These data demonstrate that Fluvastatin
induces mast cell apoptosis after a 24-hour delay that is not preceded by cell cycle arrest.

Fluvastatin Decreases SCF Survival Signals in BMMCs.
It has been published that statin-mediated apical antagonism of HMG-CoA reductase in the
cholesterol pathway not only lowers plasma cholesterol, but also the production of isoprenyl
lipids (16). This effective inhibition of the downstream farnesyl and geranylgeranyl transferases
led us to ask how the survival signals provided from cKIT (CD117) binding its ligand stem cell
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factor (SCF) are modulated by Fluvastatin. BMMCs were treated for 24-hours in cRPMI
supplemented with SCF and IL-3 at 10 ng/mL, plus either vehicle (DMSO) or Fluvastatin 10µM.
BMMCs were then starved of IL-3+SCF for four hours in cRPMI prior to SCF (200 ng/mL) restimulation. The unstimulated groups (Unstim) were treated with media alone. Whole cell lysates
were collected at 5, 15, and 30 minute intervals and Western blots for pERK1/2 and
pAKT(Ser473) were performed (Figure 2A). A representative blot shows decreased pERK when
comparing Fluvastatin treatment to vehicle (DMSO) to groups. The normalization of pERK1/2 to
total ERK1/2 was quantified as fold increase from the baseline unstimulated group (Unstim) for
each time point (Figure 2B). By comparison, AKT phosphorylation trended down at some time
points, but did not reach statistical significance. These data support the theory that inhibition of
small G-proteins has downstream effects on the cKIT-to-MAPK signaling pathway used for
survival.

Apoptosis is dependent on p53 expression and mitochondrial stability
Apoptosis is often mediated through p53 signaling originating from DNA damage, oxidative
stress or uncontrolled proliferation (17). Here we examined the role of p53 by using p53deficient (“knockout” (KO)) BMMCs compared to their background- and age-matched C57BL/6
counterparts. BMMCs were cultured in either vehicle (DMSO) or Fluvastatin (10μM) in cRPMI
with IL-3 and SCF at 10 ng/mL over a 72-hour time course. It was found that p53KO BMMCs
compared to C57BL/6 wild type (WT) underwent significantly less apoptosis when treated with
Fluvastatin (Figure 3A). Since p53 activation can induce mitochondrial damage, and statins have
been shown to induce mitochondrial dysfunction (11), we sought to determine the effect of
overexpressing the anti-apoptotic mitochondrial protein Bcl-2. We cultured age- and strainmatched Bcl-2 transgenic and C57BL/6 WT BMMCs in cRPMI with IL-3 and SCF at 10 ng/mL
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over a 72-hour time course and measured apoptosis via PI-DNA. This showed that the Bcl-2
transgenic BMMCs displayed significantly less apoptosis than C57BL/6 WT BMMCs (Figure
3B). These results indicate a role for the p53-mitocondrial pathway in Fluvastatin-mediated
apoptosis.

Fluvastatin induces cyto-protective autophagy in BMMCs
It has been widely published that statins cause autophagy in a variety of cell types (2). Since
autophagy can promote or inhibit apoptosis, we assessed Fluvastatin-induced mast cell
autophagy. One measure of autophagy is the accumulation of cleaved light chain associated
microtubule (LC3 II), as detected by Western blotting. Chloroquine raises lysosomal pH and
inhibits lysosomal fusion, allowing autophagy-induced LC3 II to accumulate. Because mast cells
undergo constitutive autophagy (18), we used chloroquine treatment alone to determine the
baseline amount of LC3 II present, and compared this to cells receiving the known autophagy
inducer Rapamycin as a positive control. Figure 4A shows an increase of LC3 II following 24hour chloroquine treatment, confirming the basal level of autophagy. As expected,
Rapamycin+chloroquine increased LC3 II levels. Importantly, Fluvastatin+chloroquine induced
more LC3 II than chloroquine alone, suggesting that Fluvastatin increases basal autophagy.
Western blot normalization to GAPDH is displayed in Figure 4B. These data suggest that
Fluvastatin elicits autophagy in primary mast cells at time point preceding apoptosis.
To determine how autophagy affects Fluvastatin-induced apoptosis, we blocked
autophagy with chloroquine or bafilomycin A, and measured sub-diploid DNA content.
Bafilomycin A1 inhibits the vacuolar H+ pump, preventing degradation of the sequestered
components of autophagy. BMMCs were treated for 48-hours in IL-3&SCF plus vehicle
(DMSO) or Fluvastatin in combination with chloroquine 10μM (CQ) or bafilomycin A1
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(200nM) (Figure 4C, 4D). We found that chloroquine or bafilomycin A1 alone slightly
increased apoptosis, and that each significantly enhanced Fluvastatin-mediated apoptosis. These
data suggest that Fluvastatin-induced autophagy is cyto-protective in primary mast cells, since its
blockade increased cell death.

Fluvastatin induces apoptosis in transformed mast cells.
We next determined if Fluvastatin-induced apoptosis extended to neoplastic mast cells. P815
mastocytoma cells were cultured in either vehicle (DMSO) or a dose response of Fluvastatin
prior to collection at 96-hours for analysis with PI-DNA staining (Figure 5A). Nearly 80% of
the cells were killed by this treatment, with an IC50 between 2.5-5μM, similar to BMMCs. Time
course analysis also revealed a slightly slower apoptotic response than primary mast cells
(Figure 5B) and a modest but significant G2 arrest at the 24-hour time point preceding apoptosis
(Figure 5C).

Fluvastatin treatment causes loss of mitochondrial potential and release of caspase 9
in transformed mast cells.
Because Fluvastatin-induced apoptosis was suppressed by Bcl-2 overexpression in BMMC, we
investigated the effect of Fluvastatin on mitochondrial stability in P815 cells. Cells were treated
for 48-hours in vehicle (DMSO) or Fluvastatin and stained with Di(OC6)3, a dye with high
affinity for the mitochondria. Decreased staining indicates loss of the trapped dye, consistent
with mitochondrial membrane damage. P815 cells treated with Fluvastatin at .625μM or 10μM
exhibited diminished Di(OC6)3 staining compared to vehicle-treated cells (Figure 6A). Given
this indication of mitochondrial damage, we next assessed the presence of active caspase 9,
which results from mitochondrial leakage. P815 cells were treated for 24 and 48-hour with
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vehicle (DMSO) and Fluvastatin (10μM), then assessed for active caspase activity via flow
cytometry using a fluorescently-labeled, cleavable caspase-9 peptide (Figure 6B). There was
significant caspase 9 activation at 24- and 48-hours, consistent with the mitochondrial stain data.
These data further suggest that Fluvastatin induces apoptotic cell death via a mitochondrial
pathway.

P815 cells upregulate cKIT and undergo cytotoxic autophagy in response to
Fluvastatin treatment.
P815 cell express a mutant cKIT (D814Y) that is analogous to the common human (D816V)
point mutation, and a major contributor to this neoplasm (6, 19, 20). Interestingly, we found that
Fluvastatin treatment induced a 2-fold increase in surface cKIT, peaking 24 hours after coculturing cells, which was just prior to the onset of apoptosis (Figure 7A). We postulate that this
may serve to delay apoptosis. To determine if autophagy was also occurring at this time point,
P815 cells were treated for 24-hours with vehicle or Fluvastatin (10μM) in the presence or
absence of chloroquine. Cells were stained with FITC anti-cKIT for visualization and acridine
orange for assessment of acidic vesicles, indicative of autophagic flux. We observed that
chloroquine treatment alone increased acridine orange staining, a testament of the basal
autophagic flux. Fluvastatin alone appeared to decrease acridine orange staining, perhaps
because it promoted autophagic processing to completion. In support of this,
Fluvastatin+chloroquine appeared to induce more acridine orange staining than either drug alone
(Figure 7B). To quantify and substantiate these observations, flow cytometry was used to
quantify acridine orange staining. When comparing the basal level of acridine orange staining in
the chloroquine (CQ)-treated samples to the combination of Fluvastatin and CQ, a significant
increase of MFI was observed (Figure 7C), supporting the fluorescent microscopy findings.
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Finally, we tested the functional importance of autophagy in P815 mastocytoma cells undergoing
Fluvastatin-mediated apoptosis. In contrast to our findings with primary mast cells, chloroquine
decreased Fluvastatin-mediated apoptosis by more than 50% (Figure 7D). These data argue that
autophagy is cytotoxic in P815 cells, since its blockade reduces apoptosis, and suggest that drugs
promoting autophagy might be useful in treating mast cell neoplasia.

Discussion
Mast cells fulfill their primary immunological functions in defense against bacterial and parasitic
infections. However in many disease states, environmental antigens become immunogenic and
can lead to life threating anaphylaxis. There is an early and a late phase of mast cell activation
that collectively cause immediate and long term effects such as vasodilation, capillary leakage,
and recruitment and activation of other immune cells. Mast cells can be activated through IgE
receptors when antigen aggregates receptor-bound IgE. The early phase of activation occurs
when pre-formed granules containing histamine and proteases are released, causing increased
vascular permeability and vasodilation. The late phase follows 4-6 hours later, and is elicited by
cytokine and chemokine production (21, 22).
Clinical studies have shown correlations between asthmatic/allergic patients on statin
therapy and reduced emergency department visits for their respective ailments (5, 23). The apical
antagonism of HMG-CoA reductase by statins in the cholesterol pathway also reduces
geranylgeranyl pyrophosphate and farnesyl pyrophosphate production. These isoprenoid lipids
are coupled to Ras, Rac and Rho, and are critical to their function (16). The loss of isoprenylation
results in production of small G-proteins without membrane anchorage, resulting in a lack of signal
transduction following a ligand-receptor interaction. Mechanisms possibly explaining statin anti-
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allergic effects include our recent demonstration that Fluvastatin decreases MAPK and AKT
signaling pathways activated by IgE crosslinking, with some genotypic constraints (14, 15). In
longer time courses, we noted that significant percentages of bone marrow derived mast cells
(BMMCs) underwent apoptosis when treated with statins, prompting the current studies.
This work shows that primary mast cells treated with Fluvastatin undergo a p53-dependent
apoptosis, but with no discernible cell cycle arrest. Additionally, data from Bcl-2 transgenic
BMMCs suggests that stabilizing the mitochondria blocks Fluvastatin-induced death. These
findings, coupled with data suggesting a cyto-protective phenotype of autophagy, support the
possibility that autophagy results from mitochondria damage, a form of autophagy called
mitophagy. In this model, increased apoptosis following autophagy blockade is a result of the cell’s
inability to dispose of damaged mitochondria through mitophagy. Damaged mitochondria release
reactive oxygen species (ROS) and have decreased oxidative phosphorylation, both detrimental to
cellular heath and homeostasis (24-26). In addition there are publications showing that Bcl-2 and
other anti-apoptotic proteins exit the mitochondria and transit to the endoplasmic reticulum (ER)
to become recycled and shuttled to other mitochondria in the cell. Thus autophagy not only protects
cells from ROS and metabolic dysfunction, but also controls sensitivity to apoptosis in the cell
(27).
The process of mitophagy involves proteins such as PINK1 and Parkin. The presence of
these proteins is often used to validate mitophagy (24). The use of confocal microscopy to assess
the co-localization of mitochondrial and lysosomal dyes in conjunction with etiology-specific
proteins are the next direction necessary in supporting this theory. Signaling data shown in figure
2 also support the known interaction of MAPK and the AKT-mTOR axis in mast cells, which are
tasked with the tagging pro-apoptotic (BH3 only) proteins such as Bim for proteasome degradation
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in mast cells (28-30). The decreased activity in the MAPK pathway supports this as a plausible
mechanism for the increase of Bim or other pro-apoptotic proteins, which in turn antagonize Bcl2, leading to the release of cytochrome C and caspase activation. In addition, the trend toward a
decrease of AKT-PI3K-mTOR axis needs to be further investigated, given studies describing the
importance of TORC1 in primary mast cell homeostasis, and TORC2 signaling as a staple in
neoplastic states. Additionally, TORC2 activation was found to positively regulate AKT signaling
resulting in an amplification of proliferation in neoplastic mast cells (31). This signaling pathway
merits further investigation to determine the effect of Fluvastatin on TORC2. These findings have
assisted in unraveling mast cell biology and begun to shed light on the molecular mechanism of
how statin therapies and autophagy inhibitors may have therapeutic effects on mast cell-associated
disease.
The findings our lab made with statin therapy on primary mast cells led us to become
interested in the potential efficacy of statins on transformed mast cells. The P815 model used in
our study conforms to several aspects of the mast cell leukemia diagnosis, including expression
of the mutant cKIT receptor, which causes constitutive growth factor-independent proliferation
(32, 33). There has been considerable research employing statin therapy with various cancer
types, particularly those with mutant K-Ras or B-Raf. For example, one observational study
found that non-small cell lung carcinoma (NSCLC) patients who were on statins had a better
survival outcome compared with those on standard treatment (2, 12, 13, 34-39).
The mechanism of Fluvastatin-induced apoptosis in P815 cells was similar to primary
cells, with indications of mitchondrial damage. However, autophagy inhibitors decreased
Fluvastatin-induced apoptosis, which was the opposite of our observations with primary mast
cells. These results suggest a cytotoxic role of autophagy in this system, a difference that can be
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potentially explained with observations in this study and the current literature. Mutant cKIT
(D816V) leads to strong MAPK, PI3K-mTOR, and STAT5 signaling critical for mast cell
survival (40). In Figure 7 it was shown that Fluvastatin treatment caused significant upregulation
of the mutant cKIT receptor, possibly as a survival mechanism. These data, coupled with
findings in the literature that oncogenic cKIT signals cause endoplasmic reticulum (ER) stress,
suggest autophagy might enhance the toxicity of statins (19, 20). The autophagic necessity to
sequester and degrade ER components due to stress could abrogate the oncogenic KIT signals
upregulated in the P815 cell line. This mechanism may support and provide a biological
explanation for the anti-apoptotic phenomenon seen with the use of autophagy inhibitors.
Additional research needed to substantiate this theory should include western blots of the SCF
pathway and visualization of cKIT signal sequestration in ER autophagosomes (omegasomes)
via confocal microscopy or immunoprecipitation of KIT in association with autophagic markers
like LC3 or p62.
Understanding the role of statin-mediated autophagy in both primary and transformed
mast cells will allow researchers and clinicians to modulate autophagy appropriately as an
adjuvant therapy in allergic and neoplastic conditions. A thorough understanding of the biology
behind statin-mediated apoptosis could allow the use of small molecular targets to avoid some
known side-effects of statin therapy such as rhabdomyolysis (41). For example, knowledge
gained in further studies could guide drug selectivity for either geranylgeranyl or farnesyl
pyrophosphate branches of the cholesterol synthesis pathway. This knowledge could have the
potential to reveal new targets, reduce dangerous side effects, and exploit autophagy correctly in
allergic or neoplastic conditions.
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Figure 1
Fluvastatin induces apoptosis in C57BL/6 BMMCs.
BMMCs were co-cultured with Fluvastatin at a concentration of 10µM in a 72hr time course.
Apoptosis was evidenced via flow cytometry PI-DNA staining through the presence of for subdiploid DNA. (Figure 1A) A dose response of Fluvastatin was conducted at the 72hr time point
on the BMMCs and apoptosis was measured via flow cytometry via PI-exclusion. (Figure 1B)
BMMCs were co-cultured with Fluvastatin in a dose response and analyzed via flow cytometry
for the presence of caspase 3/7 at 72hrs. (Figure 1C) BMMCs were co-cultured with Fluvastatin
at 10µM for 72hrs and analyzed for cell cycle progression via PI-DNA staining. (Figure 1D)
This figure is representative of three independent experiments (N=3). A student’s t-Test was
conducted and statistical significance is as depicted: *P≤0.05, **P≤0.01, ***P≤0.001,
****P≤0.0001
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Figure 2
Fluvastatin Decreases SCF signaling pathway in BMMCs.

C57BL/6 BMMCs were treated for 24hrs with Fluvastatin (Fluva) or vehicle (DMSO) and then
starved for 4 hours prior to SCF stimulation (200ng/mL). Whole cell lysates were collected after
5, 10, or 15 minutes of SCF activation with the exception of the unstimulated group (Unstim).
ERK 1/2 and AKT were probed by Western blotting. (Figure 2A). Normalization of
phosphorylated: total protein quantified as fold induction over minutes of SCF stimulation
(200ng/mL) (Figure 2B). This figure is representative one experiment (N=3). A student’s t-Test
was conducted and statistical significance is as depicted: *P≤0.05, **P≤0.01, ***P≤0.001,
****P≤0.0001
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Figure 3
Apoptosis is dependent on p53 expression and mitochondrial stability.
C57BL/6 background p53KO with age-matched WT C57BL/6 BMMCs were co-cultured with
Fluvastatin 10μM over a 72-hour time course (Figure 3A). (Representative N=1) C57BL/6
background Bcl-2 transgenic with age matched C57BL/6 BMMCs were co-cultured with
Fluvastatin 10μM over a 72-hour time course. Apoptosis was evidenced by the presence of subdiploid DNA identified via flow cytometry and PI-DNA staining. (Figure 3B). Figure3A is
representative of two independent experiments (N=3). Figure 3B is representative of three
independent experiments (N=3). A student’s t-Test was conducted and statistical significance is
as depicted: *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001
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Figure 4
Fluvastatin induces cyto-protective autophagy in BMMCs
C57BL/6 BMMCs were treated for 24-hours with vehicle (DMSO), chloroquine 10μM (CQ),
rapamycin 200nM (rapa), or Fluvastatin 10μM alone or in combination. Whole cell lysates were
collected and western blots were conducted for LC3I/II (Figure 4A). LC3 II protein levels
normalized to GAPDH quantified in (Figure 4B). C57BL/6 BMMCs were co-cultured with
vehicle (DMSO), chloroquine 10μM (CQ), bafilomycin A1 (BAF A1), or Fluvastatin 10μM
(Fluva) alone or in combination for 48-hours. (Figure 1C,D) Figure 4A and 4B are
representative of one experiment with N=3. Figure 4C is representative of three independent
experiments (N=3). Figure 4C is representative of two independent experiments (N=3). A
student’s t-Test was conducted and statistical significance is as depicted: *P≤0.05, **P≤0.01,
***P≤0.001, ****P≤0.0001
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Figure 5
Fluvastatin induces apoptosis in transformed mast cell lines.
P815 cells were treated with vehicle (DMSO) or increasing doses of Fluvastatin during a 96-hour
dose response prior to PI-DNA staining for apoptosis (sub-diploid DNA) (Figure 5A). P815
cells were co-cultured in vehicle (DMSO) or Fluvastatin at 10μM for a 96-hour time course and
analyzed via PI-DNA staining for apoptosis and cell cycle arrest (Figure 5B,C). This figure is
representative of three independent experiments (N=3). A student’s t-Test was conducted and
statistical significance is as depicted: *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001
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Figure 6
Fluvastatin treatment causes loss of mitochondrial potential and release of caspase 9 in
transformed mast cells.
P815 cells were treated for 48-hours with vehicle (DMSO) or Fluvastatin at 10µM or .625µM
and then stained with Di(OC6)3 for analysis of mitochondrial potential. A histogram
representation and a graph displaying the mean florescence intensity (MFI) (Figure 6A). P815
cells were treated with vehicle (DMSO) or Fluvastatin 10µM for 24 and 48-hours and then
assessed for caspase 9 presence via flow cytometry (Figure 6B). This figure is representative of
three independent experiments. A student’s t-Test was conducted and statistical significance is as
depicted: *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001

34
A.

B.

Vehicle

Fluva

CQ

Fluva+CQ

35
C.

D.

36

Figure 7
P815 cells exhibit pro-survival upregulation of D814V cKIT and cyto-toxic autophagy.
P815 cells were treated with either vehicle (DMSO) or Fluvastatin 10µM for 6, 12, 24, and 48hours before cKIT receptor staining (Figure 7A). P815 cells were treated with (DMSO),
chloroquine 10µM (CQ), Fluvastatin 10µM (Fluva), or Fluvastatin 10µM with chloroquine
10µM for 24-hours. Prior to fluorescent microscopy, P815 cells were stained with FITC anticKIT, and acridine orange (Figure 7B) and mean florescence intensity (MFI) from flow
cytometry of acridine orange staining conditions displayed in fluorescent imaging (Figure 7C).
P815 cells were treated for 72-hours with vehicle (DMSO), chloroquine 10µM (CQ), Fluvastatin
10µM (Fluva), and the combination treatment of chloroquine 10µM with Fluvastatin 10µM
(Figure 7D). All figure 7A, 7B, 7C, and 7D are representative of three independent experiment
(N=3). A student’s t-Test was conducted and statistical significance is as depicted: *P≤0.05,
**P≤0.01, ***P≤0.001, ****P≤0.0001

37

References
1. 2006. Effects of Statin Therapy on the Development and Progression of Heart Failure:
Mechanisms and Clinical Trials. Journal of Cardiac Failure 12: 664.
2. Zhang, J., Z. Yang, L. Xie, L. Xu, Xu, and X. Liu. 2012. Statins, autophagy and cancer
metastasis. The international journal of biochemistry & cell biology 45.
3. Takai, Y., T. Sasaki, and T. Matozaki. 2001. Small GTP-binding proteins. Physiol Rev 81:
153–208.
4. Huang, C.-C., W.-L. Chan, Y.-C. Chen, T.-J. Chen, K.-T. Chou, S.-J. Lin, J.-W. Chen, and H.B. Leu. 2010. Statin use in patients with asthma: a nationwide population-based study. European
Journal of Clinical Investigation 41.
5. Alexeeff, S. E., A. A. Litonjua, D. Sparrow, P. S. Vokonas, and J. Schwartz. 2007. Statin use
reduces decline in lung function: VA Normative Aging Study. American Journal of Respiratory
and Critical Care Medicine 176.
6. Horny, H.-P., K. Sotlar, and P. Valent. 2007. Mastocytosis: state of the art. Pathobiology 74.
7. Gewirtz, D. A. 2013. Autophagy and senescence in cancer therapy. Journal of Cellular
Physiology 229.
8. S. E. Holt, and L. W. Elmore. 2008. Accelerated senescence: an emerging role in tumor cell
response to chemotherapy and radiation. Biochemical pharmacology.
9. Kroemer, G., G. Mariño, and B. Levine. 2010. Autophagy and the integrated stress response.
Molecular Cell 40.
10. Nakano, H., and H. Ushio. 2011. An unexpected role for autophagy in degranulation of mast
cells. Autophagy 7.
11. Tricarico, P., Crovella, S., and Celsi, F. 2015. Mevalonate Pathway Blockade, Mitochondrial
Dysfunction and Autophagy: A Possible Link. International Journal of Molecular Sciences 16:
16067.
12. Horiguchi, A., M. Sumitomo, J. Asakuma, T. Asano, T. Asano, and M. Hayakawa. 2004. 3hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for
prophylaxis of renal cancer metastasis. Clinical Cancer Research 10.
13. Paragh, G., P. Kertai, P. Kovacs, Paragh, G., P. Fülöp, and G. Foris. 2003. HMG CoA
reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats.
Anticancer research 23.
14. Kolawole, E. M., J. J. A. McLeod, V. Ndaw, D. Abebayehu, B. O. Barnstein, T. Faber, A. J.
Spence, M. Taruselli, A. Paranjape, T. T. Haque, A. A. Qayum, Q. A. Kazmi, D. S. Wijesinghe,
J. L. Sturgill, C. E. Chalfant, D. B. Straus, C. A. Oskeritzian, and J. J. Ryan. 2016. Fluvastatin

38

Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects. The Journal of
Immunology 196: 1461.
15. Fujimoto, M., T. Oka, T. Murata, M. Hori, and H. Ozaki. 2008. Fluvastatin inhibits mast cell
degranulation without changing the cytoplasmic Ca2+ level. European journal of pharmacology
602.
16. Chow, S. C. 2009. Immunomodulation by statins: mechanisms and potential impact on
autoimmune diseases. Archivum Immunologiae et Therapiae Experimentalis 57.
17. . 2007. p53 in health and disease. Nature Reviews Molecular Cell Biology 8: 275.
18. Ushio, H., T. Ueno, Y. Kojima, M. Komatsu, S. Tanaka, A. Yamamoto, Y. Ichimura, J.
Ezaki, K. Nishida, S. Komazawa-Sakon, F. Niyonsaba, T. Ishii, T. Yanagawa, E. Kominami, H.
Ogawa, K. Okumura, and H. Nakano. 2011. Crucial role for autophagy in degranulation of mast
cells. Journal of Allergy and Clinical Immunology 127.
19. Obata, Y., S. Toyoshima, E. Wakamatsu, S. Suzuki, S. Ogawa, H. Esumi, and R. Abe. 2014.
Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic
mast cell proliferation. Nature Communications 5: 5715.
20. Harir, N., C. Boudot, K. Friedbichler, K. Sonneck, R. Kondo, S. Martin-Lannerée, L. Kenner,
M. Kerenyi, S. Yahiaoui, V. Gouilleux-Gruart, J. Gondry, L. Bénit, I. Dusanter-Fourt, K.
Lassoued, P. Valent, R. Moriggl, and F. Gouilleux. 2008. Oncogenic Kit controls neoplastic mast
cell growth through a Stat5/PI3-kinase signaling cascade. Blood 112.
21. . 1986. IgE Anaphylaxis.
22. Kalesnikoff, J. 2010. Anaphylaxis: Mechanisms of Mast Cell Activation.
23. Tse, S. M., L. Li, M. G. Butler, V. Fung, E. O. Kharbanda, E. K. Larkin, W. M. Vollmer, I.
Miroshnik, D. Rusinak, S. T. Weiss, T. Lieu, and A. C. Wu. 2013. Statin exposure is associated
with decreased asthma-related emergency department visits and oral corticosteroid use.
American Journal of Respiratory and Critical Care Medicine 188.
24. Roberts, R. F., M. Y. Tang, E. A. Fon, and T. M. Durcan. 2016. Defending the mitochondria:
the pathways of mitophagy and mitochondrial-derived vesicles. The International Journal of ….
25. Youle, R. J., and D. P. Narendra. 2011. Mechanisms of mitophagy. Nature Reviews
Molecular Cell Biology 12: 9.
26. . 2016. Mitophagy: Mechanisms and Role in Human Disease. The Journal of Pathology.
27. Saita, S., M. Shirane, and K. I. Nakayama. 2013. Selective escape of proteins from the
mitochondria during mitophagy. Nature Communications 4: 1410.
28. Westerberg, C. M., H. Hägglund, and G. Nilsson. 2012. Proteasome inhibition upregulates
Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V
mutation. Cell Death and Disease 3: e417.

39

29. Karlberg, M., M. Ekoff, V. Labi, A. Strasser, D. Huang, and G. Nilsson. 2010. Pro-apoptotic
Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell
apoptosis. Cell Death and Disease 1: e43.
30. Moller, C. 2005. Stem cell factor promotes mast cell survival via inactivation of FOXO3amediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic
protein Bim. Blood 106: 1330.
31. Smrz, D., M.-S. Kim, S. Zhang, B. A. Mock, S. Smrzová, W. DuBois, O. Simakova, I.
Maric, T. M. Wilson, D. D. Metcalfe, and A. M. Gilfillan. 2011. mTORC1 and mTORC2
differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood
118.
32. Taylor, M. L., J. Dastych, D. Sehgal, and M. Sundstrom. 2001. The Kit-activating mutation
D816V enhances stem cell factor–dependent chemotaxis. Blood 98: 1195.
33. Tsujimura, T., T. Furitsu, M. Morimoto, and K. Isozaki. 1994. Ligand-independent activation
of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point
mutation. Blood 83: 2619–2626.
34. LIU, H., Z. WANG, Y. LI, W. LI, and Y. CHEN. 2013. Simvastatin prevents proliferation
and bone metastases of lung adenocarcinoma in vitro and in vivo. Neoplasma 60: 240.
35. Sorscher, S. 2014. Clinical confirmation of an anti-metastasis effect from statins. The
international journal of biochemistry & cell biology 57: 207.
36. Cardwell, C. R., B. M. Hicks, C. Hughes, and L. J. Murray. 2014. Statin Use After Colorectal
Cancer Diagnosis and Survival: A Population-Based Cohort Study. Journal of Clinical Oncology
32: 3177.
37. Duma, N., M. Kang, K. Abu-Ihweij, C. Moaz, M. DosSantos, A. Gandhi, and M. Gutierrez.
2015. Effect of Statins and Metformin on Survival in Patients With Non-small Cell Lung Cancer
(NSCLC). Chest 148: 594A.
38. Thurnher, M., O. Nussbaumer, and G. Gruenbacher. 2012. Novel aspects of mevalonate
pathway inhibitors as antitumor agents. Clinical Cancer Research 18: 3524–3531.
39. Cardwell, C. R., U. M. Menamin, C. M. Hughes, and L. J. Murray. 2015. Statin Use and
Survival from Lung Cancer: A Population-Based Cohort Study. Cancer Epidemiology
Biomarkers & Prevention 24: 833.
40. Shelburne, C. P., M. E. McCoy, R. Piekorz, V. Sexl, K.-H. Roh, S. M. Jacobs-Helber, S. R.
Gillespie, D. P. Bailey, P. Mirmonsef, M. N. Mann, M. Kashyap, H. V. Wright, H. J. Chong, L.
A. Bouton, B. Barnstein, C. D. Ramirez, K. D. Bunting, S. Sawyer, C. S. Lantz, and J. J. Ryan.
2003. Stat5 expression is critical for mast cell development and survival. Blood 102.
41. Omar, M. A., and Wilson, J. P. 2002. FDA Adverse Event Reports on Statin-Associated
Rhabdomyolysis. The Annals of Pharmacotherapy 36: 288.

40

Vita

Patrick A. Paez
908 Perry St. Unit 202 Richmond VA, 23224
(Mobile) – (571) 229-0582
paezpa@vcu.edu
Born November 24, 1989 in Westchester, New York.
Education
Northern Virginia Community College, Woodbridge, Virginia


Emergency Medical Technician (2007)

Virginia Commonwealth University, Richmond, Virginia
(Undergraduate Degrees)



Pre-Medicine
Bachelors of Science in Psychology (2012)

Georgetown University Medical Center and George Mason University G², Manassas,
Virginia
(Graduate Degree)


Advanced Biomedical Sciences (2013)

Virginia Commonwealth University, Richmond, Virginia


Masters in Biology (current)

Certifications and Qualifications


Emergency Medical Technician



Advanced Cardiac Life Support from American Heart (ACLS)



American Heart Association: CPR for the Healthcare Provider



Health Care Insurance Portability and Accountability Act (HIPPA)

41


Bilingual: Spanish (Proficiently read ,write and speak)



Dedicated, creative professional with excellent interpersonal and communication skills.



Able to rapidly and efficiently adjust to new and unpredictable situations.



Phlebotomy technician



Proficient with Microsoft programs.



Proficient with Cerner and Connect Care electronic medical record programs. (EMR)



Red Cross Lifeguard Certified



Certified Pool Operator

Awards


American Association of Immunology (AAI) trainee abstract award (2014)



American Association of Immunology (AAI) trainee abstract award (2015)



American Red Cross Life Saver Recipient for actions taken on 1/16/2014



Fairfax County Fire and Rescue Citizen Life Saver Award



Fairfax County Glen McCarthy Award (2008)

Work Experience
Virginia Commonwealth University, Richmond, Virginia



August 2014-Current

Research assistant
Biology laboratory teaching assistant.

Lifetime Athletic, Centreville, Virginia
2014)

(April 2013-August

42



Aquatics Department Head
o Manage lifeguards in respect to budgeting and scheduling.
o Train staff for healthcare related emergencies.
o Run swim lesson program with monthly financial goals critical in budgeting payroll.
o Create and grow new programs within the department budget to create revenue.
o Hiring skilled staff for coaching and other competitive swimming related tasks.
o Training of staff in regards to customer service and retention with clients.
o Maintenance of licensure and mechanical function of filters.
o Daily testing with DPD-FAS reagents.
o Maintaining current knowledge of county regulations and requirements.
o Fostering business relationships with maintenance and monthly chemical delivery
companies.

Bon Secours Richmond Health System, Richmond, Virginia


Emergency Medical Technician, Emergency Department
o
o
o
o
o
o

(July 2011-August 2012)

Trained on psychiatric and cardiac arrest codes.
Performed vitals.
Phlebotomy.
Insertion of IV lines.
Casting and splinting of fractures and sprains.
Communicated with patients and documented procedures using Connect Care
(EMR) services.

Molecular Medicine Research Building (MMRB), Richmond, Virginia
August 2012)




(December 2010-

Research Lab Assistant
o Worked with laboratory animals.
o Fluent in research, and Microsoft programs.
o Performed various biotechniques.
o Competent with various immunological assays and tests. (ELISA’s, flow
cytometry, preparing vaccines with various adjuvants in sterile conditions and
isolating serum from patients and mice.)
o Worked under Dr. Dan Conrad.

MCV Hospital, Richmond, Virginia
Emergency Medical Technician, Radiology Department
(September 2010August 2010)
o Transported and provided care for patients from cardiac procedure areas to back to
ICU or floors.

43

o Gained experience with in hospital terminology and treatments for critical care
patients.


Care Partner, Acute Care Medicine (Critical Care Hospital, MCV)
(May 2010August 2010)
o Performed all phlebotomy, vitals every six hours or PRN and assisted patients with
medical care.
o Emergency department rotations as a medic occurred as needed to supplement staff.

Tuckahoe Volunteer Rescue Squad, Richmond, Virginia


Emergency Medical Technician
April 2010)
o Provided emergency medicine
o Attended the Emergency Vehicle Operator Course (EVOC)

(August 2009-

Northern Virginia Pools, Chantilly, Virginia


Pool Manager
(May 2008August 2008)
o Managed employees in regards to scheduling and training.
o Pool systems operator: Regulated pool chemical levels to state regulations and
performed maintenance of filters and pumps.

Life Time Fitness, Centreville, Virginia


Aquatics Supervisor
(September 2005May 2008)
o Managed employees in regards to scheduling along with providing work related
medical instruction.
o Pool systems operator: Regulated pool chemical levels to state regulations and
performed maintenance of filters and pumps.
o Provided customer service for patrons in and was in charge of any and all issues
on deck.

